Literature DB >> 10698507

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

F Hayakawa1, M Towatari, H Kiyoi, M Tanimoto, T Kitamura, H Saito, T Naoe.   

Abstract

We have recently identified an internal tandem duplication of the human Flt3 gene in approximately 20% of acute myeloid leukemia (AML) cases. In the present study, the wild-type and the mutant Flt3 genes were transfected into two IL-3-dependent cell lines, 32D and BA/F3 cells. Mutant Flt3-transfected cells exhibited autonomous growth while wild-type Flt3-transfected cells with the continuous stimulation of Flt3 ligand exhibited a minimal proliferation. Cells expressing mutant Flt3 showed constitutive activation of STAT5 and MAP kinase. In contrast, Flt3 ligand stimulation caused rapid activation of MAP kinase but not STAT5 in cells expressing wild-type Flt3. Finally, we found constitutive activation of MAP kinase and STAT5 in all clinical samples of AML patients with mutant Flt3. Our study shows the significance of internal tandem duplication of Flt3 receptors for leukemia cell expansion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698507     DOI: 10.1038/sj.onc.1203354

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  157 in total

1.  RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Hirozumi Sano; Akira Shimada; Tomohiko Taki; Chisato Murata; Myoung-Ja Park; Manabu Sotomatsu; Ken Tabuchi; Akio Tawa; Ryoji Kobayashi; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

2.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 3.  The Evolving AML Genomic Landscape: Therapeutic Implications.

Authors:  Sachi Horibata; George Alyateem; Christin B DeStefano; Michael M Gottesman
Journal:  Curr Cancer Drug Targets       Date:  2020       Impact factor: 3.428

4.  Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.

Authors:  Akihiro Abe; Hitoshi Kiyoi; Manabu Ninomiya; Tomio Yamazaki; Takuhei Murase; Kazutaka Ozeki; Momoko Suzuki; Fumihiko Hayakawa; Akira Katsumi; Nobuhiko Emi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

Review 5.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

6.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

7.  FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Authors:  Lei Wang; Wei-lai Xu; Hai-tao Meng; Wen-bin Qian; Wen-yuan Mai; Hong-yan Tong; Li-ping Mao; Yin Tong; Jie-jing Qian; Yin-jun Lou; Zhi-mei Chen; Yun-gui Wang; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

8.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Authors:  Keith W Pratz; Takashi Sato; Kathleen M Murphy; Adam Stine; Trivikram Rajkhowa; Mark Levis
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

9.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Authors:  Michele S Redell; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Beverly J Lange; David J Tweardy; Soheil Meshinchi
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

10.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.